JP2013209427A - Loxoprofen-containing oral composition - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a loxoprofen-containing oral composition which reduces gastric mucosa disorder caused by loxoprofen.SOLUTION: There are provided an oral composition containing 1-10 pts.wt. of glucosamine hydrochloride and 1 pt.wt. of loxoprofen, and/or an oral composition containing 1.5-10 pts.wt. of chondroitin sulfate sodium salt and 1 pt.wt. of loxoprofen. In the oral composition, preferably, the content of loxoprofen is usually 10-400 mg in the case of a solid preparation, and preferably the content of loxoprofen is 0.1-200 mg/mL in the case of a liquid preparation.

Description

  The present invention relates to an oral composition containing loxoprofen and glucosamines and / or chondroitins.

  Nonsteroidal antipyretic analgesic / anti-inflammatory drugs (hereinafter referred to as NSAIDs) such as loxoprofen, ibuprofen, and aspirin have a pharmacological action mechanism that suppresses the biosynthesis of prostaglandins, and therefore inevitably cause the side effect of gastric mucosal disorder. Is well known. Therefore, in order to reduce gastric mucosal damage caused by NSAID, a method in which an antacid, a gastric mucosa protective agent, a proton pump inhibitor, a histamine H2 receptor antagonist or the like is used in combination is generally known.

  Although loxoprofen is a prodrug, it is considered to cause less gastric mucosal damage compared to other NSAIDs. However, in actual medical practice, in order to avoid gastric mucosal damage in advance, as with other NSAIDs. The above combination prescription may be performed.

  Also, knee osteoarthritis is a disease in which the cartilage of the knee joint wears down with age and causes arthritis and deformity, and pain occurs. Become. As this drug therapy, NSAID is generally used or used externally in the medical field. However, there are some NSAIDs that inhibit the synthesis of proteoglycan, which is a major component of cartilage, and promote the degradation of proteoglycan, but loxoprofen does not inhibit the synthesis of proteoglycan. It has been reported that it has an excellent aspect of suppressing proteoglycan degradation (see Non-Patent Document 1).

  On the other hand, in the over-the-counter drugs, vitamin B1 main drug formulations effective for joint pain are those containing sodium chondroitin sulfate as an active ingredient and glucosamine hydrochloride as an additive ingredient. Furthermore, in recent years, many supplements have been sold that expect to regenerate articular cartilage by ingesting glucosamine and chondroitin, which are constituents of articular cartilage, and thus imply treatment or prevention of osteoarthritis of the knee. Is well known.

  As a composition related to the present invention, a composition containing ibuprofen and glucosamine hydrochloride and a composition further containing sodium chondroitin sulfate are disclosed, and it has been reported that the analgesic action is enhanced by this (patent) Reference 1). However, to date, no composition containing loxoprofen and glucosamines and / or chondroitin is known, and there is no report that gastric mucosal damage caused by loxoprofen is reduced by the combined use of glucosamine and chondroitin. There is no suggestion.

JP 2006-290812 A

Pharmacology and therapy, Vol. 16, no. 8, 1988, p. 149

  It is useful if the gastric mucosal damage caused by loxoprofen can be reduced, and it is more beneficial if the gastric mucosal damage can be reduced easily and inexpensively. Further, against the background of the aging society, there is a demand for more effective treatment and prevention of knee osteoarthritis.

  The present inventor has been diligently researching for this purpose. As a result, it has been surprisingly found that when loxoprofen is used in combination with glucosamines and / or chondroitins, gastric mucosal damage due to loxoprofen is suppressed or enhanced depending on the content thereof, and shows complex behavior. Furthermore, it has been found that when glucosamines and / or chondroitins are contained at a predetermined ratio, gastric mucosal damage due to loxoprofen is remarkably suppressed, and the present invention has been completed.

  In general, it is known that NSAIDs can reduce gastric mucosal damage to some extent if taken after meals. However, antipyretic and anti-inflammatory analgesics are essentially useless, and it is inherently difficult to be limited to taking them after meals. Therefore, it is meaningful to embody a loxoprofen formulation with reduced gastrointestinal disturbances, especially more useful for patients who need to take for a long period of time or who have restricted their diet and water intake. It is.

The present invention is (1) an oral composition characterized by containing loxoprofen and glucosamines and / or chondroitins,
(2) An oral composition comprising 0.2 parts by weight or less of glucosamine or 0.8 parts by weight or more per 1 part by weight of loxoprofen,
(3) An oral composition comprising 1 to 4 parts by weight of glucosamine per 1 part by weight of loxoprofen,
(4) An oral composition characterized by containing chondroitin at 0.6 parts by weight or less, or 1.3 parts by weight or more per 1 part by weight of loxoprofen,
(5) An oral composition characterized by containing 1.5 to 4 parts by weight of chondroitin per 1 part by weight of loxoprofen,
(6) The oral composition according to any one of (1) to (5), wherein loxoprofen is sodium loxoprofen,
(7) The oral composition according to any one of (1) to (5), wherein loxoprofen is loxoprofen sodium dihydrate,
(8) The oral composition according to any one of (1) to (7), wherein the glucosamine is glucosamine hydrochloride,
(9) The oral composition according to any one of (1) to (8), wherein the chondroitin is sodium chondroitin sulfate,
(10) The oral composition according to any one of (1) to (9) for use as an antipyretic and / or analgesic with reduced gastric mucosal damage caused by loxoprofen,
(11) The oral composition according to any one of (1) to (9) for use as an anti-inflammatory agent with reduced gastric mucosal damage caused by loxoprofen,
(12) The oral composition according to any one of (1) to (9) for use as a cold remedy with reduced gastric mucosal damage caused by loxoprofen,
(13) The oral composition according to any one of (1) to (9), which is used as a therapeutic and / or prophylactic agent for knee osteoarthritis with reduced gastric mucosal damage caused by loxoprofen object,
(14) The oral composition according to any one of (1) to (13), which is administered between meals,
(15) The oral composition according to any one of (1) to (13), which is administered to a patient who needs to take for a long time, and (16) a meal Oral composition according to any one of (1) to (13), wherein the composition is administered to a patient whose intake of water is restricted.

  The “oral composition” in the present invention means a composition that is orally administered to an animal (preferably a human) and is preferably used as a medicine.

  The “salt” of the present invention, when the active ingredient of the present invention has an acidic group or basic group, can be converted into a basic salt or acidic salt by reacting with a base or acid. Indicates salt.

  The “basic salt” is preferably an alkali metal salt such as sodium salt, potassium salt or lithium salt; an alkaline earth metal salt such as magnesium salt or calcium salt; N-methylmorpholine salt, triethylamine salt, Organic base salts such as tributylamine salt, diisopropylethylamine salt, dicyclohexylamine salt, N-methylpiperidine salt, pyridine salt, 4-pyrrolidinopyridine salt, picoline salt or glycine salt, lysine salt, arginine salt, ornithine salt, glutamic acid Salts, amino acid salts such as aspartate, preferably alkali metal salts.

  As the “acid salt”, preferably, hydrohalide such as hydrofluoride, hydrochloride, hydrobromide, hydroiodide, nitrate, perchlorate, sulfate, Inorganic acid salts such as phosphates; lower alkane sulfonates such as methane sulfonate, trifluoromethane sulfonate and ethane sulfonate, aryl sulfones such as benzene sulfonate and p-toluene sulfonate Acid salt, acetate salt, malate salt, fumarate salt, succinate salt, citrate salt, ascorbate salt, tartrate salt, succinate salt, maleate salt and the like; and glycine salt, lysine salt , An arginine salt, an ornithine salt, an amino acid salt such as glutamate and aspartate, and more preferably a hydrochloride, hydrobromide or sulfate.

  The “derivative” of the present invention refers to a derivative because, when the active ingredient of the present invention has a functional group, it can be made into a derivative by reacting the functional group with a protective group or the like. Derivatives include, for example, acyl groups and other esters, preferably acetyl groups and sulfate esters.

  The active ingredient of the present invention may absorb moisture by adhering to the atmosphere or recrystallize, and may adsorb water or become hydrate. Are also used in the present invention.

  The “loxoprofen” of the present invention is loxoprofen and a salt thereof, preferably loxoprofen sodium, and more preferably loxoprofen sodium dihydrate.

  The “glucosamines” of the present invention are glucosamine and derivatives thereof and salts thereof. Examples of the “derivative” include N-acetylglucosamine, and examples of the “salt” include glucosamine hydrochloride and glucosamine sulfate. The glucosamine of the present invention is preferably glucosamine hydrochloride. Glucosamine is a kind of amino sugar made from glucose in the body and is a constituent of chondroitin.

  The “chondroitins” of the present invention are chondroitin and derivatives thereof, and salts thereof. Examples of the “derivative” include chondroitin sulfate, and examples of the “salt” include sodium chondroitin sulfate. The chondroitin of the present invention is preferably sodium chondroitin sulfate. Chondroitin is a component of proteoglycan that is one of the components constituting cartilage.

  The term “gastric mucosal disorder” of the present invention refers to disorders of the upper gastrointestinal tract including gastric mucosal lesions (eg, hemorrhage, bleeding, edema) and gastric ulcers resulting from acute and chronic gastritis, and the duodenum, which is an adjacent site of the stomach. .

  The “treatment” of the present invention is to cure or ameliorate the disease or symptom or suppress the symptom, and “prevention” is to prevent the onset of the disease or symptom.

  The “between meals” in the present invention means between meals or when hungry.

  The “patient that needs to be taken for a long period of time” of the present invention is not particularly limited as long as it is a patient who is taken for the purpose of preventing or treating a chronic disease. For example, rheumatoid arthritis, deformable knee joint, etc. And patients with chronic stiff shoulders and low back pain.

  The “patient with restricted intake of food and water” of the present invention is particularly limited if the intake of food and water is restricted compared to normal cases for the purpose of disease prevention and treatment. However, there may be mentioned patients with acute and chronic nephritis, artificial dialysis, peritoneal dialysis, diabetic kidney disease and the like.

  The oral composition containing the loxoprofen of the present invention and glucosamines and / or chondroitins in a predetermined ratio has an excellent alleviating effect on gastric mucosal damage caused by loxoprofen. Therefore, the oral composition of the present invention can be administered between meals as an antipyretic agent, analgesic agent, inflammatory treatment agent, cold treatment agent, knee osteoarthritis treatment agent and / or prophylactic agent, or for a long period of time. It is safer and more useful to administer to patients who need to take it and those who have limited intake of food and water.

The graph which shows the relationship between the ratio of the dosage of glucosamine hydrochloride or sodium chondroitin sulfate with respect to the dosage of loxoprofen sodium dihydrate (50 mg / kg) and the ulcer inhibition rate%.

  Loxoprofen sodium is listed in the 15th revised Japanese Pharmacopoeia. Further, other salts and hydrates of loxoprofen can be produced by known methods.

  Sodium chondroitin sulfate is listed in the Japanese Pharmacopoeia Pharmaceutical Standard 2002.

  Glucosamine hydrochloride is listed in the Pharmaceutical Additives Dictionary 2005.

  The single dose of loxoprofen varies depending on the indication and age, but is usually 20 mg to 180 mg, which is administered 1 to 3 times a day.

  When the composition of the present invention is a solid preparation, the content of loxoprofen is usually 10 mg to 400 mg, preferably 20 mg to 180 mg.

  When the composition of the present invention is a liquid preparation, the content of loxoprofen is usually 0.1 mg / mL to 200 mg / mL, and preferably 1 mg / mL to 100 mg / mL.

  The content ratio of glucosamines is preferably 0.2 parts by weight or less, or 0.8 parts by weight or more, and more preferably 1 part by weight or more with respect to 1 part by weight of loxoprofen. The upper limit is not particularly limited, but is preferably 10 parts by weight or less, and more preferably 4 parts by weight or less.

  The content ratio of chondroitins is preferably 0.6 parts by weight or less, or 1.3 parts by weight or more, and more preferably 1.5 parts by weight or more with respect to 1 part by weight of loxoprofen. The upper limit is not particularly limited, but is preferably 10 parts by weight or less, and more preferably 4 parts by weight or less.

  In the present invention, in addition to the above active ingredients, as needed, hypnotic sedatives, antitussives, expectorants, antihistamines, antiallergic drugs, sympathomimetic drugs, parasympathomimetic drugs, anti-inflammatory enzymes, vitamins, Herbal medicines and the like can be contained as long as the effects of the present invention are not impaired.

  Specific examples of these dosage forms include tablets, fine granules (including powders), capsules, liquids (including syrups) and the like, and additives and base materials suitable for each dosage form. Can be used according to the usual methods described in the Japanese Pharmacopoeia and the like.

  In the above dosage forms, various commonly used additives can be used depending on the dosage form. For example, an excipient, a stabilizer, a coating agent, a lubricant, an adsorbent, a binder, a disintegrant, a surfactant, a colorant, a pH adjuster, and a fragrance can be added.

  Hereinafter, the present invention will be described in more detail with reference to Examples and Test Examples, but the scope of the present invention is not limited thereto.

Example 1 Tablet (1) Ingredient (Table 1)
1 to 2 tablets (mg) (1a) (1b) (1c)
----------------------------------
Loxoprofen sodium dihydrate 60 60 60
Glucosamine hydrochloride 120-60
Sodium chondroitin sulfate-180 90
Corn starch 50 50 50
Magnesium stearate appropriate amount appropriate amount appropriate amount ----------------------------------
(2) Manufacturing method Take the above ingredients and quantity, and manufacture tablets according to the section of the Japanese Pharmacopoeia General Rules for “Pharmaceuticals”.

(Example 2) Fine granule (1) component (Table 2)
In 1 package (mg) (2a) (2b) (2c)
----------------------------------
Loxoprofen sodium dihydrate 60 60 60
Glucosamine hydrochloride 120-60
Sodium chondroitin sulfate-180 90
Hydroxypropyl cellulose 100 100 100
Corn starch 50 50 50
Magnesium stearate appropriate amount appropriate amount appropriate amount ----------------------------------
(2) Manufacturing method The above ingredients and quantities are taken, and a fine granule is produced according to the section of the Japanese Pharmacopoeia General Formulation “Granule”.

Example 3 Capsule (1) Ingredient (Table 3)
In 1 capsule (mg) (3a) (3b) (3c)
----------------------------------
Loxoprofen sodium dihydrate 60 60 60
Glucosamine hydrochloride 120-60
Sodium chondroitin sulfate-180 90
Hydroxypropyl cellulose 40 40 40
Polysorbate 80 10 10 10
Magnesium stearate appropriate amount appropriate amount appropriate amount ----------------------------------
(2) Manufacturing method After taking the above-mentioned components and quantities, and producing a fine granule according to the paragraph of the Japanese Pharmacopoeia General Formulation “Granule”, the capsule is filled into a hard capsule.

(Example 4) Syrup (1) component (Table 4)
In 50 mL (mg) (4a) (4b) (4c)
----------------------------------
Loxoprofen sodium dihydrate 60 60 60
Glucosamine hydrochloride 120-60
Sodium chondroitin sulfate-180 90
Sodium benzoate 130 130 130
Citric acid 60 60 60
Concentrated glycerin 40 40 40
Purified water remainder remainder remainder ----------------------------------
(2) Manufacturing method Take the above components and quantities, and manufacture a syrup according to the Japanese Pharmacopoeia General Formulation “Syrup”, then fill it into a brown glass bottle to manufacture a syrup.

(Test Example 1)
Test of inhibitory effect of loxoprofen on gastric mucosal damage (1) Test substance Loxoprofen sodium dihydrate is from Sankyo Co., Ltd., glucosamine hydrochloride is from Sigma Chemical, chondroitin sulfate sodium is from Tokyo A product made by Kasei Kogyo Co., Ltd. was used.
Each test substance was prepared by suspending or dissolving in 0.5% tragacanth solution on the test day. The administration volume was orally administered at 5 mL per 1 kg body weight, and the same amount of 0.5% tragacanth was administered to the control group.

(2) Animals Environmental control breeding equipment purchased from Wistar-Imamichi male rats (Animal Breeding Research Institute) at 5 weeks of age and controlled at a temperature of 20 to 26 ° C., a humidity of 30 to 70%, and a lighting time of 7:00 to 19:00 5-6 animals were placed in a stainless steel rat breeding gauge, and the animals were fed with feed (mouse / rat breeding F-2, Funabashi Farm) and tap water freely passed through a water filter. After preliminary breeding for 8 days, the health condition was observed macroscopically on the day before the test, and after selecting good animals, the animals were randomly divided into 5 groups per group.

(3) Method The 100% gastric mucosal disorder expression dose in the loxoprofen sodium dihydrate single agent was calculated | required previously, and the following tests were done based on the dose.
The test substance was orally administered to animals fasted from 16:00 on the day before the test, and 3.5 hours later, the carotid artery was exsanguinated under ether anesthesia, and the stomach was removed. The stomach was cut along the large vagina, washed gently with physiological saline, and then observed for bleeding spots with a stereomicroscope (Olympus 10 × 10 times).
As the ulcer index, the major axis of bleeding spots was measured in units of 0.5 mm, and the total of each animal was determined. Based on the ulcer index in the loxoprofen sodium dihydrate single administration group and the ulcer index in the glucosamine hydrochloride or chondroitin sodium combination group, the ulcer suppression rate was determined from the following equation.

A: Ulcer index of loxoprofen sodium dihydrate alone administration group based on 100% gastric mucosa disorder expression level B: Ulcer index of combination group Loxoprofen sodium dihydrate 100% gastric mucosal disorder expression level is 50 mg / Kg. The following test results are based on these doses.

(4) Test results Tables 5 and 6 and Fig. 1 show the results of the ulcer suppression rates of the obtained combination groups. Each value is an average value of 5 animals per group.
Loxoprofen in the tables and figures is loxoprofen sodium dihydrate, glucosamine is glucosamine hydrochloride, chondroitin is sodium chondroitin sulfate, and the content ratio is the dose of each drug to loxoprofen sodium dihydrate 50 mg / Kg. .

(Table 5)
Test substance (dose: mg / Kg) Content ratio Ulcer inhibition rate (%)
------------------------------------
Loxoprofen (50) + Glucosamine (5) 0.1 10
Loxoprofen (50) + Glucosamine (25) 0.5 -21
Loxoprofen (50) + Glucosamine (50) 1.0 13
Loxoprofen (50) + Glucosamine (100) 2.0 43
Loxoprofen (50) + Glucosamine (200) 4.0 52
------------------------------------
From Table 5 and FIG. 1, when loxoprofen and glucosamine are used in combination, the content ratio is larger than 0.2, and there is a fact other than worsening ulcer in a range smaller than 0.8, and the content ratio is 1 From the above, it was found that an excellent ulcer suppressing action was exhibited.

(Table 6)
Test substance (dose: mg / Kg) Content ratio Ulcer inhibition rate (%)
------------------------------------
Loxoprofen (50) + chondroitin (5) 0.1 12
Loxoprofen (50) + Chondroitin (25) 0.5 1
Loxoprofen (50) + chondroitin (50) 1.0-14
Loxoprofen (50) + Chondroitin (100) 2.0 29
Loxoprofen (50) + Chondroitin (200) 4.0 56
------------------------------------
From Table 6 and FIG. 1, when loxoprofen and chondroitin are used in combination, there is a fact that the content ratio is larger than 0.5 and the ulcer is worsened in a range smaller than 1.3, and the content ratio is 1 It was proved that an excellent ulcer-suppressing action was exhibited at .5 or higher.

  The present invention can be administered to oral compositions with reduced risk of gastric mucosal damage (especially for patients who require administration between meals or for long periods of time, and patients whose intake of food or water is restricted). Antipyretic, analgesic, inflammatory treatment, cold treatment, or osteoarthritis treatment and / or prevention agent).

Claims (2)

  An oral composition comprising 1 to 10 parts by weight of glucosamine hydrochloride per 1 part by weight of loxoprofen. An oral composition comprising 1.5 to 10 parts by weight of sodium chondroitin sulfate per 1 part by weight of loxoprofen.